IL6 and congenital rubella syndrome: The central role of IL-6 trans-signaling in pathologic processes mediated by multi-cytokine cascades is further supported by the efficacy of the anti-IL-6Rα antibody tocilizumab in the treatment of rheumatoid arthritis [24] and cytokine release syndrome (CRS) induced by administration of therapeutic chimeric antigen receptor T cells (CAR-T) [25].